The pharmaceutical propranolol, also marketed under the name Inderal, is a member of the beta-blocker group of medications.
It is mostly used to treat cardiac rhythm problems, excessive blood pressure, and other cardiovascular diseases like angina and heart failure. It functions by preventing the heart and blood arteries from being affected by the hormone adrenaline, which can lower blood pressure and lessen the strain on the heart.
Propranolol has been used off-label to treat anxiety, stage fright, migraines, and tremors in addition to its cardiovascular applications. Some forms of glaucoma may also be treated with it.
Like other medicines, propranolol may have unwanted effects, some of which include low blood pressure, depression, sexual dysfunction, lethargy, dizziness, and low blood pressure.
It should be taken with caution in patients with asthma or other respiratory disorders since it may also hide the signs of low blood sugar in diabetics.
Global Propranolol market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.
Propranolol has recently gained interest for its ability to treat children’s PTSD symptoms. Randomized clinical trials are necessary, nonetheless, to verify its efficacy.
Additionally, as they may reduce the longevity of patients with cirrhosis, nonselective beta-blockers like propranolol should be stopped or avoided in patients with intractable ascites.
Although propranolol is typically well taken, it can have unwanted effects like vivid or strange nightmares, angina flare-ups, and in rare cases, heart attacks. Elderly individuals could be more vulnerable to these consequences.
Inflammation is one of the many abnormalities that COVID-19 patients experience because the SARS-CoV-2 virus compromises the immune system. Beta-blockers may assist to lessen this inflammation and restore the immune system’s balance.
A common beta-blocker called metoprolol may be helpful in treating COVID-induced ARDS, according to a study that was published in the Journal of the American College of Cardiology.
COVID-19 patients with ARDS were randomised to receive metoprolol medication or to be in a control group that got no further care.The findings imply that metoprolol may be a straightforward and affordable treatment for ARDS in COVID patients.
© Copyright 2017-2023. Mobility Foresights. All Rights Reserved.